C1q, the first component of complement, and leukocyte-associated Ig-like receptor 1 (LAIR-1; CD305), an inhibitory receptor expressed on hematopoietic cells, have both been associated with arrest of monocyte-derived dendritic cell (DC) differentiation and inhibition of Toll-like receptor activity in plasmacytoid DCs. Defects in both molecules have been implicated in susceptibility to, and progression of, systemic lupus erythematosus. Inhibitory signaling partners for C1q on monocytes and DCs remain undefined. Because C1q contains collagen-like motifs and LAIR-1 is a universal collagen receptor, we hypothesized that C1q is a functional ligand for LAIR-1. Binding analyses in cell-free systems and on the cell membrane demonstrate that C1q and its collagen tail associate with LAIR-1 and LAIR-2 (CD306), a soluble inhibitor of LAIR-1. Both C1q and its collagen tail trigger phosphorylation of LAIR-1 immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in monocytes. Functional analyses show that C1q-mediated inhibition of monocyte-DC differentiation and C1q-mediated inhibition of IFN-α production by plasmacytoid DCs were both reversed by LAIR-2. Moreover, C1q-mediated inhibition of DC differentiation was reversed by LAIR-1 siRNA. Thus, C1q is a functional ligand for LAIR-1 restricting immune cell differentiation and activation. The discovery of C1q interactions with LAIR-1 and LAIR-2 lends much needed insight into molecular mechanisms operating to prevent the loss of tolerance, particularly in systemic lupus erythematosus.
C1q, the first component of complement, and leukocyte-associated Ig-like receptor 1 (LAIR-1; CD305), an inhibitory receptor expressed on hematopoietic cells, have both been associated with arrest of monocyte-derived dendritic cell (DC) differentiation and inhibition of Toll-like receptor activity in plasmacytoid DCs. Defects in both molecules have been implicated in susceptibility to, and progression of, systemic lupus erythematosus. Inhibitory signaling partners for C1q on monocytes and DCs remain undefined. Because C1q contains collagen-like motifs and LAIR-1 is a universal collagen receptor, we hypothesized that C1q is a functional ligand for LAIR-1. Binding analyses in cell-free systems and on the cell membrane demonstrate that C1q and its collagen tail associate with LAIR-1 and LAIR-2 (CD306), a soluble inhibitor of LAIR-1. Both C1q and its collagen tail trigger phosphorylation of LAIR-1 immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in monocytes. Functional analyses show that C1q-mediated inhibition of monocyte-DC differentiation and C1q-mediated inhibition of IFN-α production by plasmacytoid DCs were both reversed by LAIR-2. Moreover, C1q-mediated inhibition of DC differentiation was reversed by LAIR-1 siRNA. Thus, C1q is a functional ligand for LAIR-1 restricting immune cell differentiation and activation. The discovery of C1q interactions with LAIR-1 and LAIR-2 lends much needed insight into molecular mechanisms operating to prevent the loss of tolerance, particularly in systemic lupus erythematosus.
autoimmunity | immunologic tolerance C 1q, which initiates the classic complement pathway, also exhibits a variety of complement-independent activities (1). These include facilitating phagocytosis and regulating cellular differentiation, survival, migration, and cytokine secretion (1) (2) (3) (4) (5) . An immunosuppressive role for C1q is supported by the high frequency of C1q-deficient individuals who develop systemic lupus erythematosus (SLE) (6) . C1q not only opsonizes apoptotic debris to prevent SLE (1, 6) but suppresses IFN-α production by plasmacytoid dendritic cells (pDCs) in SLE (4, 5) . Reports that C1q engages cellular C1q receptors to inhibit differentiation of monocytes to DCs (7, 8) provide further evidence that C1q may directly interact with immune cells to induce tolerance and inhibit autoimmunity.
C1q is composed of 18 polypeptide chains (6A, 6B, and 6C chains). Each polypeptide contains a C-terminal globular head region (gC1q) and N-terminal collagen-like Gly-Pro-Hyp (GPO) repeat region (CLR) (9) . Several receptors for C1q have been identified, including CD93 (C1qRp), CD35 (CR1), gC1qR (p33), α2β1 integrin, calreticulin (cC1qR), and CD91 (1) . Cell-associated receptors described to date for both gC1q and CLR do not exhibit intracellular inhibitory signaling domains, and the identification of C1q receptors on the plasma membrane with intracellular inhibitory signaling capacity has remained elusive.
Leukocyte-associated Ig-like receptor 1 (LAIR-1; CD305), a transmembrane protein belonging to the Ig superfamily, is expressed on both myeloid and lymphoid cells (10, 11) . Its extracellular domain binds to collagen, particularly GPO collagen motifs, in a hydroxyproline-dependent manner (10) . Because collagen is abundant in ECM, it has been presumed that LAIR-1 is activated in tissue-bound cells. It has been proposed that during a normal response to tissue injury, ECM collagens engage LAIR-1-expressing cells to suppress inappropriate immune activity (10) . The LAIR-1 intracellular domain contains two immunoreceptor tyrosine-based inhibitory motifs (ITIMs); when these are phosphorylated, they recruit the phosphatases Src homology 2 domaincontaining protein tyrosine phosphatase (SHP)-1 and SHP-2, which, in turn, negatively regulate intracellular signaling associated with immune cell maturation, differentiation, and activation (10-13). All ECM collagens tested thus far are ligands for LAIR-1 (10). LAIR-1-mediated inhibitory signaling of monocyte-to-DC differentiation and DC function has been typically studied using antibodies to bind and cross-link surface LAIR-1; thus, natural ligands for LAIR-1 on these cells are still poorly defined.
LAIR-1 ligation, like C1q, inhibits molecular processes required for GM-CSF-and IL-4-driven monocyte-to-DC differentiation and Toll-like receptor (TLR)-induced IFN-α production by pDCs (7, 8, 14, 15) . Evidence that disrupted LAIR-1-mediated immune silencing leads to a loss of self-tolerance in disease settings includes deficient LAIR-1 expression on pDCs and B cells in SLE, correlating with increased IFN-α production and defective regulation of B-cell antibody secretion, respectively, and increased levels of LAIR-2 (a soluble LAIR-1 inhibitor) in rheumatoid arthritis (14, 16, 17) . Based on the increasingly evident contribution of LAIR-1 and C1q to immune homeostasis, the extent of shared activities of LAIR-1 and C1q, and the presence of numerous potential LAIR binding sites on the CLR of C1q, we hypothesized that LAIR-1 binds C1q to suppress immune cell activity. We now show that high-affinity binding occurs between C1q and LAIR-1 and that biological activities associated with C1q and LAIR-1 interactions include inhibition of monocyte-to-DC differentiation and pDC activation. Moreover, our results indicate that LAIR-2 may be an important regulator of the C1q and LAIR-1 interaction.
Results
Demonstration of C1q-LAIR-1 and C1q-LAIR-2 Binding in Cell-Free Systems. The association of LAIR with collagen is of high affinity, and a single collagen molecule contains about 10 binding sites for LAIR-1 (18, 19) . Based on these observations, we predicted that C1q would exhibit direct binding to LAIR-1 through the CLR. Because LAIR-2 regulates LAIR-1 activity by competing for its ligand (19) , we also asked whether LAIR-2 would bind C1q. We studied direct interactions between C1q and LAIR using surface plasmon resonance (SPR). As illustrated in the sensorgrams ( Fig. 1 A-C) , the pronounced changes in the refractive index over time demonstrated specific binding between LAIR-1 or LAIR-2 and C1q. Determination of the affinity dissociation constants (K d s) revealed a K d of 1.7 × 10 −7 M for the interaction of human LAIR-1 and C1q (Table 1) . That affinity constant falls within the range previously described for LAIR-1 binding to collagens or GPO peptides (18, 20, 21) . In agreement with previous reports that LAIR-2 and LAIR-1 are both capable of binding to GPO (19) , SPR analysis revealed specific binding between LAIR-2 and C1q, although the binding affinity was not as strong as that noted for LAIR-1 ( Fig. 1C and Table 1 ). SPR results were confirmed by dot blot analysis showing concentration-related binding between LAIR-1 and C1q (Fig. 1D) . Dot blot assays also confirmed enhanced reactivity of C1q to LAIR-1 compared with LAIR-2 (Fig. 1D) . Additionally, concentration-related binding to LAIR occurred with the C1q collagen tail (Fig. 1 E-G) . Like intact C1q, the collagen tail exhibited greater binding to LAIR-1 than to LAIR-2 (Fig. 1G) , and binding of LAIR-1 to the C1q tail was less pronounced than to intact C1q. Collectively, these data demonstrate that C1q directly associates with both LAIR-1 and LAIR-2. The stronger binding of the intact C1q molecule compared with the C1q tail may indicate that other residues not present in the pepsin-digested C1q fragment may favor a configuration that has enhanced affinity for LAIR-1.
HEK293T Cells Transfected with LAIR-1 and THP-1 LAIR-1 hi Cells Bind C1q Through LAIR-1. We used distinct cellular models to investigate if soluble C1q (endotoxin-low, free of antigenic cargo) engages cell-associated LAIR-1. Nonhematopoietic HEK293T cells lacking LAIR-1 and the CD91 receptor for the C1q collagen tail were transfected with LAIR-1 ( Fig. 2A) . HEK293T LAIR-1 pos cells, but not HEK293T LAIR-1 neg cells, bound fluorochrome-labeled C1q in a concentration-dependent manner (Fig. 2B ) There was also binding of LAIR-1 pos HEK293 T cells to the C1 complex (Fig. 2C ). LAIR-2 and unlabeled C1q competitively inhibited binding of labeled C1q (Fig. 2 D and E) . THP-1 (a human acute monocytic leukemia cell line) cells constitutively expressing LAIR-1 exhibited strong binding of fluorescent C1q (Fig. 2F) ; this interaction was Table 1 . (D) Dot blots show concentration-dependent associations between biotinylated intact C1q (10 μg/mL) and LAIR-1 and LAIR-2. Binding of biotinylated-C1q collagen tail (20 μg/mL) to immobilized LAIR-1 (E) or LAIR-2 (F). A representative experiment is shown (n = 3). (G) Verification that LAIR-1 and LAIR-2 bind to C1q collagen tail by solid-phase microtiter plate assays using LAIR-1, LAIR-2, or BSA-coated wells (5 μg/mL). ***P < 0.0001. also blocked by soluble LAIR-2 in a concentration-dependent fashion (Fig. 2G) . Further substantiating that C1q is a ligand for cell associated LAIR-1, siRNA knockdown of LAIR-1 expression resulted in significantly reduced binding of C1q to both THP-1 cells and freshly prepared human monocytes ( Fig. 2 H and I) . These results establish that binding between soluble C1q/C1 and LAIR-1 occurs at the cell surface. + DCs lacking the monocyte marker CD14 (Fig. 3C ). This differentiation arrest was also mediated by C1 (Fig. 3C ). In Fig. 3 D and E, C1q and C1 increased LAIR-1 and CD14 expression as revealed by quantitative RT-PCR and decreased production of the proinflammatory cytokines IL-6 and TNF-α. Preincubation of C1q with LAIR-2 significantly decreased LAIR-1 and CD14 expression, suggesting that LAIR-2 reversed the C1q-mediated DC differentiation arrest (Fig. 3G) .
Another inhibitory function shared by C1q and LAIR-1 is the ability to suppress the production of IFN-α by pDCs obtained from either healthy individuals or individuals with SLE (4, 5, 14) . As shown in Fig. 4 , addition of C1q to human pDCs that were stimulated with CpG oligonucleotides reduced IFN-α expression both at the protein and RNA levels in a dose-dependent fashion (Fig.  4A ). LAIR-2 reversed the C1q-mediated IFN-α production in pDCs (Fig. 4B) .
To confirm that the inhibitory effects of C1q required that C1q binds LAIR-1, we demonstrated that inhibitory effects of C1q were diminished when LAIR-1 expression was decreased. C1q-mediated blockade of DC differentiation was reversed with reduced LAIR-1 expression due to treatment with LAIR-1 siRNA. In contrast to control siRNA, monocytes transfected with LAIR-1 siRNA did not display C1q-associated CD14 and LAIR-1 expression ( Fig. 5 A and B) . We further demonstrated that C1q-mediated inhibition of cytokine secretion was dependent on its interaction with LAIR-1 because siRNA-transfected primary monocytes demonstrated decreased secretion of IL-6 and TNF-α (Fig. 5C ). Together with our findings showing reduced C1q binding to monocytes transfected with LAIR-1 siRNA (Fig. 2I) , these data confirm that the C1q and LAIR-1 interaction alters monocyte function.
Discussion
These studies demonstrate that C1q binds to both LAIR-1 and LAIR-2 and that the C1q-LAIR-1 interaction contributes to the C1q-mediated arrest of monocyte-to-DC differentiation and the inhibition of pDC activation. Although it has been known that ECM collagen is a tissue ligand for LAIR-1, our results establish that C1q is a soluble ligand for LAIR-1 and reveal the potential for C1q-mediated immunoinhibitory activity through LAIR-1 signaling. Indeed, it may be that collagen is normally the major ligand for LAIR-1 in tissue, but in blood, and locally in tissue under conditions characterized by increased synthesis of C1q, C1q may be a major ligand for LAIR-1. Our data show that the physiological consequences of C1q LAIR-1 molecular interactions on monocytes, monocyte-derived DCs, and pDCs include phosphorylation of ITIM motifs on LAIR-1, inhibition of monocyte-to-DC differentiation, suppression of DC-derived proinflammatory cytokines, and inhibition of TLR-mediated IFN-α production by pDCs. Two of these inhibitory functions, monocyte-to-DC maturation arrest and suppression of cytokine production by DCs, clearly depend on C1q binding to LAIR-1 because inhibition no longer occurs when cellular levels of LAIR-1 are decreased. A recent study showed that the C1q collagen-like tail can inhibit inflammasome activation in DCs (22) ; whether this activity depends on LAIR-1 is not yet known. It is possible, in fact likely, that other inhibitory receptors for the C1q collagen-like tail or gC1q exist and may engage in cross-talk with LAIR-1.
Because both gC1q receptors and LAIR-1 are present on freshly isolated monocytes and gC1q has been shown to engage gC1q cellular receptors directly (1, 23, 24) , it is possible that binding of gC1q to gC1q receptors contributes to the avidity of the C1q interaction with LAIR-1 and to the cross-linking of LAIR-1. Notwithstanding, the inhibitory activity prompted by anti-LAIR-1 antibodies that promote LAIR-1 cross-linking indicates that engagement of gC1q is not required for LAIR-1 activation. It is interesting to speculate, however, that LAIR-1 cross-linking by C1q to distinct gC1q receptors may activate different downstream signaling pathways and contribute to the diversity of LAIR-1 inhibitory effects in distinct settings and cell types. We are currently investigating whether C1q engages other inhibitory receptors besides LAIR-1 on monocytes that are activated by C1q. Although α2β1 integrins bind collagens and may function as C1q receptors, they lack an intracellular ITIM domain (1, 25) . LAIR-2, which has been shown to be increased in certain autoimmune settings (17) , also bound C1q and blocked C1q effects on cell differentiation and activation. Thus, LAIR-2 may be a key physiological regulator of C1q and LAIR-1 interactions. Whether LAIR-1 shed from the cell surface after enzymatic cleavage (17) also inhibits C1q activity remains to be studied.
Our findings imply that C1q devoid of immunogenic cargo can interact with cell-associated LAIR-1 to control immune activation. Approximately 80% of C1q present in plasma occurs as a C1qrs complex, and the remaining 20% occurs as uncomplexed C1q (26) . We showed that both C1q and the C1 (C1qrs) complex engaged LAIR-1 on the cell surface and suppressed the production of proinflammatory cytokines. Therefore, C1q in either form may function in partnership with cell-associated LAIR-1 to inhibit immune cell activity. Whether C1q binds more avidly to LAIR-1 after release of C1rs from the C1 complex remains to be determined. Another important remaining question is whether C1q attached to apoptotic debris or present in immune complexes yields a distinct response. Given that a variety of cells in a range of tissues may secrete large quantities of C1q and C1 (26) , and that C1q, r and s are distinctly regulated (23) , control of local concentrations of C1q and C1 may be an important factor in determining LAIR-1 activation.
Although C1q activity and LAIR-1 activity have been separately ascribed important roles in maintaining immune homeo- pos cells as mean ± SEM from three independent experiments. (D) mRNA for CD14 and LAIR-1 is inhibited by C1q and C1 complexes. Expression was determined by quantitative RT-PCR normalized to HPRT1 as a housekeeping gene. Data are representative of three independent experiments. (E) Secretion of IL-6 and TNF-α in day 3 cultures is inhibited by C1q or C1 complex. Cytokine analysis was performed using a human proinflammatory 7-plex assay kit. Data are mean of triplicate samples ± SEM (n = 2). (F) LAIR-2 blocks LAIR-1 phosphorylation induced by C1q. C1q (20 μg/mL) was preincubated with LAIR-2 and then added to monocytes (n = 2). (G) LAIR-2 (40 μg/mL) blocks the effect of C1q (20 μg/mL) in monocyte cultures. CD14 levels were determined by flow cytometry on day 3. Data are averages of the mean fluorescence intensity of triplicate samples ± SEM (n = 2). MFI, mean fluorescence intensity. *P < 0.05; **P < 0.01. stasis and defects in either molecule have been linked with flawed immunoregulation in distinct disease settings, such as autoimmunity and cancer (16) , our studies establish a functional partnership between the two molecules. Our findings are of particular relevance to SLE. Genetic C1q deficiency represents the strongest susceptibility factor contributing to the development of SLE (5) . Even in the absence of C1q mutations, reduced serum C1q activity is common in SLE. Moreover, autoantibodies to C1q strongly correlate with severe lupus nephritis, a major morbidity of SLE. Although C1q deficiency in SLE has led to the concept that complement-independent functions of C1q include maintenance of immune tolerance, the mechanism(s) by which C1q deficiency contributes to SLE remains poorly defined, as does the means by which C1q sustains immune homeostasis in general. Because excessive immunological activation is thought to be driven by monocyte-derived DCs and pDCs in SLE, and because LAIR-1 and C1q have been independently reported to inhibit functions of both DC subtypes in a similar fashion (4, 5, 7, 14, 15) , we propose that defects in C1q and LAIR-1 interactions contribute to immune pathology in this disease.
A recent study reported the phenotype of LAIR-1-deficient C57BL/6 mice (27) . These mice did not develop a lupus-like phenotype. Of note, C1q deficiency leads to autoantibody production only in certain genetic backgrounds (28) , and the same is likely to be true for LAIR-1 deficiency. Moreover, multiple redundant pathways exist to prevent autoimmunity and, as discussed above, there may be additional inhibitory receptors for C1q. Finally, the LAIR protein family appears to differ between mice and humans. LAIR-1 expression on human B cells is well documented but appears to be restricted to marginal zone B cells in mice, suggesting that distribution of LAIR-1 may differ between species. Moreover, a LAIR-2 homolog does not exist in mice, suggesting that the interaction of C1q with LAIR-1 in mice does not demand the layered regulation that exists in humans. In preliminary studies, we have found that enhanced production of IFN-α was induced by IgM anti-DNA antibodies in vivo to a greater extent in pDCs of C1q −/− mice than WT mice, which is consistent with reported data that ingestion of IgM-opsonized apoptotic cells inhibits the activation of DCs. These data support an in vivo role for C1q and LAIR-1 interactions in mice and suggest that perhaps LAIR-1-deficient mice have not been challenged appropriately to exhibit a phenotype.
Our discovery of C1q-mediated inhibition through engagement of cell membrane LAIR-1 provides much needed insight into immunoregulatory processes controlling immunity in normal and abnormal physiology. Further studies aimed at understanding how disruption in each molecular component may contribute to disease activity will be facilitated by this understanding of their interactions.
Materials and Methods
Antibodies and Reagents. Commercially obtained fluorochrome-conjugated and unconjugated antibodies included the following: anti-human LAIR-1 (DX26; BD Pharmingen); anti-human LAIR-1 (NKTA255; BioLegend); anti-CD11c, anti-CD14, anti-CD86, and anti-HLA-DR (all from BD Pharmingen); polyclonal anti-C1q (Quidel); and isotype-matched control antibodies (BD Pharmingen). Tissue culture reagents included the following: LymphoPrep (Axis-Shield); penicillin/streptomycin, RPMI 1640, DMEM, L-glutamine, and Hepes (all from Gibco-Invitrogen); heat-inactivated FBS (HyClone); and human recombinant (hr) GM-CSF and hrIL-4 (both from Peprotech). Other reagents used included C1q purified from pooled normal human sera (Complement Technology); C1 complex (EMD Millipore Co.); hrLAIR-1 and hrLAIR-2 (both from R&D Systems); BSA, human gamma-globulin block, pepsin from porcine gastric mucosa, sodium azide, formaldehyde, and DAPI (all from Sigma); CpG ODN 2216 (Invivogen); and PBS (Gibco-Invitrogen). Proteins, tissue culture chemicals, and reagents were endotoxin-tested (<0.1 EU/mL) either by the manufacturer or by us using a limulus amebocyte lysate assay kit performed according to the manufacturer's instructions (Endosafe; Charles River).
Flow Cytometry. For flow cytometry-assisted immunofluorescence analysis of cell surface-associated markers, cells were suspended in staining buffer (PBS Purified pDCs were stimulated with or without CpG ODN2216 (2 μM), C1q (20 μg/mL), or LAIR-2 (40 μg/mL). IFN-α was measured in culture supernatants at 24 h using an IFN-α-specific ELISA or quantitative RT-PCR at 24 h. Data represent the mean ± SEM (n = 3). *P < 0.05; **P < 0.001. containing 1% BSA and 0.01% NaN 3 ); they were incubated with blocking reagent (human gamma block at 1 mg/mL) for 30 min on ice and then with fluorochrome-labeled antibodies or the appropriate isotype-matched controls for 30 min on ice. Cells were resuspended twice in cold staining buffer and then fixed in 1% formaldehyde in PBS. DAPI was added (1 μg per 100 μL) to assess apoptosis. Flow cytometry was conducted on an LSRII (BD Bioscience) or FACSCalibur (BD Bioscience), data were analyzed using CellQuest (BD Biosciences) and FlowJo software (TreeStar), and results are expressed as a percentage of positive cells or mean fluorescence intensity. For flow cytometryassisted detection of Alexa 488-labeled C1q binding to the cell surface, studies were conducted in 96-well flexible assay plates (BD Falcon) using 5 × 10 5 cells per well and increasing amounts of Alexa 488-C1q as indicated. After appropriate washes in staining buffer, the cells were fixed in 1% paraformaldehyde/ PBS and analyzed by LSRII flow cytometry.
Preparation of C1q and C1q Collagen Tail Fragments. Alexa-Fluor 488 was conjugated to C1q or C1 complex using amine-reactive probes (molecular probes; Invitrogen) as per the manufacturer's protocol. Briefly, the reaction was performed using C1q in 0.1 M sodium bicarbonate (pH 8.3). After incubating C1q for 1 h at room temperature with Alexa-Fluor 488, unbound Alexa-Fluor 488 was removed using a Zeba Desalt spin column (Thermo Scientific). Buffer exchange to PBS and sample concentration were performed using a centrifugal filter concentration unit (Amicon). The labeling efficiency for C1q conjugation of Alexa-Fluor 488 was determined by flow cytometry. The C1q collagen tail fragments were obtained by pepsin digestion as previously outlined by Reid (9) and modified by Siegel and Schumaker (29) . Briefly, C1q was dialyzed overnight in 100 mM sodium acetate buffer (pH 4.45) at room temperature. After dialysis, pepsin prepared in sodium acetate buffer (pH 4.45) was added (35.5 μg of pepsin for every 1 mg of C1q) and digestion was performed at 37°C for 20 h. Digested C1q was washed with chilled sodium acetate buffer, and the sample was adjusted to pH 7.5 with 2 N of sodium hydroxide. Buffer was exchanged for PBS through dialysis, undigested C1q and C1q pepsin digests were subjected to SDS/PAGE, and proteins were analyzed by Coomassie brilliant blue staining (Fig. S1A) . Yield was >17%, and purity was >90%. Biotin labeling of C1q or the C1q tail was performed using an EZ-Link Sulfo-NHS-LC Biotinylation kit (Thermo Scientific) per the manufacturer's instructions. Briefly, protein was dissolved in PBS and combined with freshly prepared Sulfo-NHS-LC biotin solution at the recommended ratios for 2 h on ice. Zeba Desalt spin columns were used to remove excess biotin reagent and buffer exchange, respectively. Confirmation of the biotinylation reaction was performed by ELISA using streptavidin linked to alkaline phosphatase and unlabeled and biotin-labeled C1q; results were obtained using a microplate reader set at an absorbance wavelength of 405nm. SPR Analysis. C1q was directly immobilized on BIAcore CM5 sensor chips (GE Healthcare); interactions with LAIR-1 and LAIR-2 were conducted and analyzed using a BIAcore 3000 instrument and BIAeval 3.2 (GE Healthcare) software. Binding reactions were performed in HBS-EP buffer [10 mM Hepes, 150 mM NaCl, 3 mM EDTA, and 0.01% (vol/vol) surfactant p20] (pH 7.4) from Biacore 3000 (GE Healthcare). Binding analyses were performed at flow rates of 30 μL per min at 25°C. The analytes [60 μL each of LAIR-1 (0-50 nM) in HBS-EP buffer with 0.05% P20, and LAIR-2 (0-400 nM) in HBS-EP buffer with 0.05% P20] were injected into flow cells 1 and 2, and the association of analyte and ligand was recorded. The binding was removed by injecting 50 μL of 1 M NaCl/50 mM NaOH, followed by 100 μL of HBS-EP (pH 7.4). Sensorgrams of the interaction were analyzed using BIAeval 3.2 software. The reference surface data were subtracted from the reaction surface data to eliminate refractive-index changes of the solution, injection noise, and nonspecific binding to the blank surface. A blank injection with buffer alone was subtracted from the resulting reaction surface data. Data were globally fitted to the Lagmuir model for 1:1 binding.
Slot-Blot Assay. A microsample filtration manifold apparatus (Schleicher & Schuell) housing nitrocellulose membranes was used for protein slot blotting. After assembling the apparatus, each protein was loaded (200 μL in PBS) and gentle vacuum was applied. When the wells were completely drained, nitrocellulose membranes were blocked in 2% BSA/PBS for 1 h, incubated with test protein partners for 2 h, and then washed with 0.1% Tween (Fisher Scientific) in PBS three times to remove unbound proteins. Streptavidin-conjugating Infrared 800 (LI-COR) was added for 45 min; positive signals were detected by the Odyssey Infrared Imaging system (LI-COR). For detection of purified proteins in solid phase-binding microassays, recombinant LAIR-1 (5 μg/mL) and LAIR-2 (5 μg/mL) were coated onto 96-well plates. Binding of biotinylated-C1q (20 μg/ mL) or biotinylated-C1q collagen-tail (20 μg/mL) was detected with alkaline phosphatase-labeled streptavidin. All procedures were performed at room temperature.
Cell Transfection and RNA Silencing. HEK293T cells were maintained with DMEM containing 10% FBS, 2 mM L-glutamine, 50 IU/mL penicillin, and 50 mg/ mL streptomycin, and were subcultured every 3 d. THP-1 cells, representing a human acute monocytic leukemia cell line, were cultured in RPMI 1640 containing 10% FBS, 2 mM L-glutamine, Hepes, 50 IU/mL penicillin, and 50 mg/ mL streptomycin, and were subcultured every 2 d. For transfection of the LAIR-1-negative HEK293T cells, a plasmid encoding pcDNA3.1-human LAIR-1 Fig. 5 . C1q-mediated suppression of monocyte-to-DC differentiation is decreased by LAIR-1 siRNA. Enriched monocytes were transfected with control siRNA or LAIR-1 siRNA. Viable cells were cultured in GM-CSF and IL-4 containing medium with or without C1q (20 μg/mL). (A) LAIR-1 knockdown efficiency was determined on day 1 after transfection. CD14 levels were also measured on day 1 (n = 3). MFI, mean fluorescence intensity. (B) LAIR-1 and CD14 levels were measured 3 d after transfection. Results represent mean of triplicate samples ± SEM (n = 2). (C) IL-6 and TNF-α were measured from culture supernatants obtained on day 3. Data represent mean ± SEM (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001.
(generously provided by John Coligan, National Institutes of Health, Bethesda) was used, and Lipofectamine 2000 (Invitrogen) was used according to the supplier's protocol. Transfection efficiency was routinely over 80%. In RNAi assays, THP-1 cells or human monocytes were transfected using an Amaxa Nucleofector kit (Lonza). Transfection efficiency was over 40%. Peripheral blood mononuclear cells (PBMCs) were cotransfected with GFP, and surface markers were determined on GFP pos gated cells. siRNAs for LAIR-1 or control siRNA were purchased from Qiagen. The target sequence of LAIR-1 is CAG-CATCCA GAAGGTTCGTTA. C1q binding to the cell surface of both cell lines was analyzed by flow cytometry using Alexa-488 labeled C1q as described above.
Monocyte-to-DC Differentiation. Human PBMCs, obtained according to the institutional guidelines of the Feinstein Institute for Medical Research and Farmingdale State College, State University of New York, were isolated from heparinized blood of healthy donors by density centrifugation. Monocytes were enriched using a human monocyte enrichment kit (STEMCELL Technologies). Negatively selected monocytes (1 × 10 6 cells/mL) were cultured in complete RPMI 1640 media consisting of RPMI 1640 containing 2 mM L-glutamine, 10 mM Hepes, 50 IU/mL penicillin, 50 mg/mL streptomycin, and 10% FBS with GM-CSF (50 U/mL) and IL-4 (50 ng/mL) to initiate monocyte-derived DC differentiation. C1q, C1 complex, or LAIR-2 was included as indicated. Cytokine analysis was performed using a human proinflammatory 7-plex assay ultra-sensitive kit (Meso Scale Discovery). For quantitative PCR, total RNA was extracted with an RNeasy kit (Qiagen) and subjected to reverse transcription with an iScript cDNA synthesis kit (Bio-Rad Laboratories). cDNA was analyzed by quantitative PCR using Light Cycler 480 master mix with Taqman probes (Applied Biosystems) against human CD14 (Hs02621496_s1), LAIR-1 (Hs00430498_m1), and IFN-α1 (Hs00256882_s1). Data were normalized to HPRT1; relative induction was analyzed using the delta delta Ct method.
pDCs and IFN-α Measurement. Human peripheral pDCs were purified with an EasySep kit using negative selection to enrich for HLA-DR-positive and CD304 (BDCA-4)-positive pDCs (STEMCELL Technologies). The pDCs (3 × 10 3 cells per well) were placed in complete RPMI 1640 media and stimulated with C1q, C1q plus LAIR-2, or LAIR-2 overnight. For pDC stimulation, 2 μM CpG ODN 2216 (Invivogen) was used. IFN-α was measured using a VeriKine Human IFN-α ELISA kit (PBL Interferon Source) exhibiting a sensitivity range of 12.5-500 pg/mL exactly as recommended.
Determination of LAIR-1 Phosphorylation. Monocytes (4 × 10 6 ) were stimulated with C1q or C1q collagen tail for 5 min at 37°C in complete RPMI 1640 medium, resuspended in PBS, and then lysed in buffer containing protease and phosphatase inhibitors (Thermo Scientific) for 30 min on ice. Cell lysates were incubated with human phosphoimmunoreceptor array membranes (Proteome Profiler Array; R&D Systems) according to the manufacturer's protocol. Phosphorylated proteins were detected by pan-antiphosphotyrosine antibody conjugated to HRP. Array data were developed with X-ray film and quantified by FluorChem8900 (Alpha Innotech). Phosphorylation levels of individual analytes were determined by average pixel density of duplicate spots; values were obtained after subtracting background signals and were normalized to positive controls.
Statistical Analysis Unpaired two-tailed Student t tests or two-way ANOVA was performed with Prism (GraphPad Software). Statistical significance was defined as P ≤ 0.05.
